Market closedADR
Connect Biopharma/$CNTB
Connect Biopharma shares are trading higher after the company reported its Q1 2025 financial results and provided a business update.
21 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Connect Biopharma
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
Ticker
$CNTB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
62
ISIN
US2075231017
Website
CNTB Metrics
BasicAdvanced
$40M
-
-$0.28
-0.22
-
Price and volume
Market cap
$40M
Beta
-0.22
52-week high
$1.00
52-week low
$0.51
Average daily volume
176K
Financial strength
Current ratio
11.458
Quick ratio
11.198
Long term debt to equity
0.026
Total debt to equity
0.193
Management effectiveness
Return on assets (TTM)
-12.27%
Return on equity (TTM)
-16.14%
Valuation
Price to revenue (TTM)
1.542
Price to book
0.44
Price to tangible book (TTM)
0.44
Price to free cash flow (TTM)
-1.648
Growth
Earnings per share change (TTM)
-74.90%
3-year earnings per share growth (CAGR)
-58.20%
CNTB News
AllArticlesVideos
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 days ago
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
GlobeNewsWire·3 days ago
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Connect Biopharma stock?
Connect Biopharma (CNTB) has a market cap of $40M as of May 17, 2025.
What is the P/E ratio for Connect Biopharma stock?
The price to earnings (P/E) ratio for Connect Biopharma (CNTB) stock is 0 as of May 17, 2025.
Does Connect Biopharma stock pay dividends?
No, Connect Biopharma (CNTB) stock does not pay dividends to its shareholders as of May 17, 2025.
When is the next Connect Biopharma dividend payment date?
Connect Biopharma (CNTB) stock does not pay dividends to its shareholders.
What is the beta indicator for Connect Biopharma?
Connect Biopharma (CNTB) has a beta rating of -0.22. This means that it has an inverse relation to market volatility.